Related Experiment Video
Updated: Mar 22, 2026

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
Published on: August 30, 2018
Continuous versus intermittent infusion of high-dose meropenem in critically ill patients: an observational cohort
Felix Bergmann1, Marlene Prager1, Katarina Kumpf2
1Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.
Background:
Whether continuous infusion of high-dose meropenem improves outcomes compared with intermittent infusion in critically ill patients remains unclear.
Methods:
We conducted a retrospective propensity score-matched cohort study at a tertiary academic hospital in Vienna, Austria, including critically ill patients treated with high-dose meropenem between March 2014 and April 2024. Eligible patients had an ICU stay of ≥3 days and received meropenem 6 g/day (or 4 g/d in renal impairment) as continuous or intermittent infusion. Patients were matched 1:3 using propensity scores with covariate adjustment. The primary outcome was 90-day all-cause mortality. Secondary outcomes included 30-day mortality, emergence of carbapenem resistance, initiation of extracorporeal membrane oxygenation (ECMO), new-onset acute respiratory distress syndrome (ARDS), incidence of fever, and hospital length of stay.
Results:
Among 3768 patients receiving high-dose meropenem, 597 intermittent-infusion patients were matched with 199 continuous-infusion patients. Adjusted 90-day mortality was 39.5% (95% CI, 33.1-45.9) with continuous infusion and 35.9% (95% CI, 32.4-39.4) with intermittent infusion (adjusted risk difference, 3.7%; 95% CI, -3.7 to 11.0; p = 0.33). No significant differences were observed for secondary outcomes.
Conclusions:
Continuous infusion of high-dose meropenem was not associated with improved outcomes compared with intermittent infusion in critically ill patients.
Insights
High-dose meropenem infusion strategies for critically ill patients were compared. Continuous infusion did not show improved outcomes over intermittent infusion for 90-day mortality or secondary endpoints.
Area of Science:
- Critical Care Medicine
- Infectious Diseases
- Pharmacology
Background:
- The optimal administration of high-dose meropenem in critically ill patients is debated.
- Continuous versus intermittent infusion strategies require further clinical evaluation.
Purpose of the Study:
- To compare the efficacy of continuous infusion versus intermittent infusion of high-dose meropenem in critically ill patients.
Main Methods:
- A retrospective, propensity score-matched cohort study included critically ill patients receiving high-dose meropenem (6 g/day or 4 g/day).
- Patients were matched 1:3 based on propensity scores, with 90-day all-cause mortality as the primary outcome.
Main Results:
- Matched cohorts included 199 continuous-infusion and 597 intermittent-infusion patients.
- Adjusted 90-day mortality was 39.5% for continuous infusion and 35.9% for intermittent infusion (p=0.33).
- No significant differences were found in secondary outcomes, including 30-day mortality and carbapenem resistance.
Conclusions:
- Continuous infusion of high-dose meropenem was not associated with improved clinical outcomes compared to intermittent infusion in this critically ill cohort.
- Current evidence does not support a change in meropenem administration protocols for critically ill patients based on infusion method.
Related Concept Videos
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations
Acute Pyelonephritis II: Diagnostic Studies and Management
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Continuous Renal Replacement Therapy
Peritoneal Dialysis II: Peritoneal Dialysis Systems and Complications
